Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLP006
MIFTS: 69

Sleep Apnea

Categories: Mental diseases, Neuronal diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Sleep Apnea

About this section

MalaCards integrated aliases for Sleep Apnea:

Name: Sleep Apnea 12 53 29 6 42 15 62 17
Sleep Apnea Syndromes 44 70

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Mental diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0050847
ICD9CM 34 780.57
MeSH 44 D012891
NCIt 50 C26884
SNOMED-CT 67 206750008
ICD10 32 G47.3
UMLS 70 C0037315
Sources

Summaries for Sleep Apnea

About this section
NINDS : 53 Sleep apnea is a common sleep disorder characterized by brief interruptions of breathing during sleep.  These episodes usually last 10 seconds or more and occur repeatedly throughout the night.  People with sleep apnea will partially awaken as they struggle to breathe, but in the morning they will not be aware of the disturbances in their sleep.  The most common type of sleep apnea is obstructive sleep apnea (OSA), caused by relaxation of soft tissue in the back of the throat that blocks the passage of air.  Central sleep apnea (CSA) is caused by irregularities in the brain’s normal signals to breathe.  Most people with sleep apnea will have a combination of both types.  The hallmark symptom of the disorder is excessive daytime sleepiness. Additional symptoms of sleep apnea include restless sleep, loud snoring (with periods of silence followed by gasps), falling asleep during the day, morning headaches, trouble concentrating, irritability, forgetfulness, mood or behavior changes, anxiety, and depression.  Not everyone who has these symptoms will have sleep apnea, but it is recommended that people who are experiencing even a few of these symptoms visit their doctor for evaluation.  Sleep apnea is more likely to occur in men than women, and in people who are overweight or obese.

MalaCards based summary : Sleep Apnea, also known as sleep apnea syndromes, is related to central sleep apnea and obesity-hypoventilation syndrome, and has symptoms including seizures, tremor and back pain. An important gene associated with Sleep Apnea is AHDC1 (AT-Hook DNA Binding Motif Containing 1), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Phenylephrine and Zopiclone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and tongue, and related phenotypes are cardiovascular system and behavior/neurological

Disease Ontology : 12 A sleep disorder characterized by repeated cessation and commencing of breathing that repeatedly disrupts sleep.

MedlinePlus : 42 Sleep apnea is a common disorder that causes your breathing to stop or get very shallow. Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. The most common type is obstructive sleep apnea. It causes your airway to collapse or become blocked during sleep. Normal breathing starts again with a snort or choking sound. People with sleep apnea often snore loudly. However, not everyone who snores has sleep apnea. You are more at risk for sleep apnea if you are overweight, male, or have a family history or small airways. Children with enlarged tonsils or adenoids may also get it. Doctors diagnose sleep apnea based on medical and family histories, a physical exam, and sleep study results. When your sleep is interrupted throughout the night, you can be drowsy during the day. People with sleep apnea are at higher risk for car crashes, work-related accidents, and other medical problems. If you have it, it is important to get treatment. Lifestyle changes, mouthpieces, surgery, and breathing devices can treat sleep apnea in many people. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 62 About sleep apnea: Sleep apnea (AP-ne-ah) is a common disorder in which you have one or more pauses in breathing or shallow breaths while you sleep. Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. Typically, normal breathing then starts again, sometimes with a loud snort or choking sound. Sleep apnea usually is a chronic (ongoing) condition that disrupts your sleep. When your breathing pauses or becomes shallow, you’ll often move out of deep sleep and into light sleep. As a result, the quality of your sleep is poor, which makes you tired during the day. Sleep apnea is a leading cause of excessive daytime sleepiness.

Wikipedia : 73 Sleep apnea, also spelled sleep apnoea, is a sleep disorder in which pauses in breathing or periods of... more...

Sources

Related Diseases for Sleep Apnea

About this section

Diseases in the Sleep Apnea family:

Central Sleep Apnea

Diseases related to Sleep Apnea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1365)
# Related Disease Score Top Affiliating Genes
1 central sleep apnea 32.9 REN PHOX2B NPPB LEP HCRT CRP
2 obesity-hypoventilation syndrome 32.6 LEP IL6 ADIPOQ
3 postpoliomyelitis syndrome 32.1 TNF IGF1 HCRT
4 acromegaly 32.0 LEPR LEP INS IGF1 GHRL ADIPOQ
5 polycystic ovary syndrome 31.9 LEP INS IGF1 GHRL ADIPOQ
6 congestive heart failure 31.8 TNF REN NPPB INS IL6 EDN1
7 lipid metabolism disorder 31.8 LEP INS IL6 CRP APOE ADIPOQ
8 impotence 31.8 INS EDN1 ACE
9 ischemia 31.7 NPPB HIF1A EDN1 ACE
10 apnea, obstructive sleep 31.7 TNF REN PHOX2B NPPB LEP INS
11 coronary heart disease 1 31.7 INS CRP APOE ADIPOQ ACE
12 pulmonary disease, chronic obstructive 31.6 TNF NPPB INS IL6 CXCL8 CRP
13 optic nerve disease 31.6 TNF IL6 EDN1 CRP
14 gastroesophageal reflux 31.6 TNF IL6 HTR2A GHRL CXCL8 ADIPOQ
15 post-traumatic stress disorder 31.6 HTR2A CRP APOE ADIPOQ
16 tonsillitis 31.6 TNF IL6 CXCL8
17 fatty liver disease 31.5 TNF LEPR LEP INS IL6 CXCL8
18 stroke, ischemic 31.5 TNF REN NPPB IL6 CRP APOE
19 intracranial hypertension 31.5 TNF NPPB ADIPOQ
20 mental depression 31.5 TNF INS IL6 HTR2A CRP
21 hypercholesterolemia, familial, 1 31.4 INS CRP APOE ACE
22 ankylosis 31.4 TNF HIF1A EDN1
23 mood disorder 31.4 IL6 HTR2A HIF1A ACE
24 nonarteritic anterior ischemic optic neuropathy 31.4 EDN1 CRP ACE
25 pustulosis of palm and sole 31.3 TNF CXCL8 CRP
26 liver disease 31.3 TNF LEPR LEP INS IL6 CXCL8
27 lung disease 31.3 TNF NPPB INS IL6 EDN1 CXCL8
28 proteinuria, chronic benign 31.3 REN INS ACE
29 conjunctivitis 31.3 TNF IL6 CXCL8
30 pulmonary hypertension 31.3 TNF REN NPPB IL6 HTR2A HIF1A
31 open-angle glaucoma 31.3 TNF IL6 EDN1 APOE ACE
32 acute myocardial infarction 31.3 NPPB IL6 EDN1 CRP ACE
33 patent foramen ovale 31.3 REN NPPB EDN1 CRP ACE
34 spinal cord injury 31.3 TNF IL6 CXCL8
35 narcolepsy 31.3 TNF LEP IL6 HTR2A HCRT GHRL
36 atherosclerosis susceptibility 31.3 TNF LEP INS IL6 EDN1 CXCL8
37 periodontitis 31.3 TNF IL6 CXCL8 CRP
38 covid-19 31.2 TNF NPPB IL6 CXCL8 ACE
39 sleep disorder 31.2 TNF REN LEP INS IL6 IGF1
40 sudden infant death syndrome 31.2 TNF PHOX2B IL6 HTR2A CXCL8
41 retinal vein occlusion 31.2 TNF IL6 EDN1 CXCL8 ACE
42 polycythemia 31.2 REN HIF1A EDN1 ACE
43 systolic heart failure 31.2 TNF NPPB IL6 EDN1 CRP ADIPOQ
44 bronchitis 31.2 TNF IL6 CXCL8 CRP
45 respiratory failure 31.2 TNF REN NPPB IL6 HCRT EDN1
46 arteries, anomalies of 31.2 TNF REN LEP INS IL6 EDN1
47 traumatic brain injury 31.2 IL6 IGF1 APOE
48 hypothyroidism 31.1 TNF REN LEP INS IGF1 CRP
49 nasopharyngitis 31.1 TNF INS CRP
50 cerebrovascular disease 31.1 TNF REN NPPB LEP INS IL6

Comorbidity relations with Sleep Apnea via Phenotypic Disease Network (PDN):


Bronchitis Chronic Pulmonary Heart Disease
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Pulmonary Hypertension, Primary, 1 Respiratory Failure

Graphical network of the top 20 diseases related to Sleep Apnea:



Diseases related to Sleep Apnea
Sources

Symptoms & Phenotypes for Sleep Apnea

About this section

UMLS symptoms related to Sleep Apnea:


seizures; tremor; back pain; dyspnea; apnea; headache; syncope; excessive daytime somnolence; pain; wheezing; chronic pain; sciatica; snoring; sleep disturbances; cheyne-stokes respiration; coughing; vertigo/dizziness; sleeplessness; labored breathing; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Sleep Apnea:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ACE ADIPOQ APOE CRP EDN1 HCRT
2 behavior/neurological MP:0005386 10.39 ACE ADIPOQ APOE GHRL HCRT HIF1A
3 homeostasis/metabolism MP:0005376 10.38 ACE ADIPOQ APOE CRP EDN1 GHRL
4 growth/size/body region MP:0005378 10.34 ACE ADIPOQ APOE EDN1 HCRT HIF1A
5 endocrine/exocrine gland MP:0005379 10.32 ACE ADIPOQ APOE EDN1 GHRL HIF1A
6 adipose tissue MP:0005375 10.26 ACE ADIPOQ APOE GHRL IGF1 IL6
7 immune system MP:0005387 10.23 ACE ADIPOQ APOE CRP HIF1A IGF1
8 digestive/alimentary MP:0005381 10.22 APOE EDN1 GHRL HIF1A HTR2A IL6
9 muscle MP:0005369 10.18 ADIPOQ APOE EDN1 HCRT HIF1A HTR2A
10 nervous system MP:0003631 10.1 ACE ADIPOQ APOE EDN1 HCRT HIF1A
11 integument MP:0010771 10.09 ADIPOQ APOE HIF1A IGF1 IL6 INS
12 liver/biliary system MP:0005370 10.06 ACE ADIPOQ APOE HIF1A IL6 INS
13 neoplasm MP:0002006 9.92 ACE ADIPOQ HIF1A IGF1 IL6 LEP
14 renal/urinary system MP:0005367 9.9 ACE ADIPOQ APOE EDN1 HIF1A IGF1
15 respiratory system MP:0005388 9.65 ADIPOQ APOE HCRT HIF1A IGF1 IL6
16 skeleton MP:0005390 9.36 ADIPOQ APOE EDN1 HIF1A HTR2A IGF1
Sources

Drugs & Therapeutics for Sleep Apnea

About this section

PubMed Health treatment related to Sleep Apnea: 62

Sleep apnea is treated with lifestyle changes, mouthpieces, breathing devices, and surgery . Medicines typically aren't used to treat the condition. The goals of treating sleep apnea are to: Restore regular breathing during sleep Relieve symptoms such as loud snoring and daytime sleepiness Treatment may improve other medical problems linked to sleep apnea, such as high blood pressure . Treatment also can reduce your risk for heart disease , stroke , and diabetes . If you have sleep apnea, talk with your doctor or sleep specialist about the treatment options that will work best for you. Lifestyle changes and/or mouthpieces may relieve mild sleep apnea. People who have moderate or severe sleep apnea may need breathing devices or surgery . If you continue to have daytime sleepiness despite treatment , your doctor may ask whether you're getting enough sleep . (Adults should get at least 7 to 8 hours of sleep; children and teens need more. For more information, go to the Health Topics Sleep Deprivation and Deficiency article.) If treatment and enough sleep don't relieve your daytime sleepiness, your doctor will consider other treatment options.

Drugs for Sleep Apnea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 395)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenylephrine Approved Phase 4 59-42-7 6041
2
Zopiclone Approved Phase 4 43200-80-2 5735
3
Opium Approved, Illicit Phase 4 8008-60-4
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Ephedrine Approved Phase 4 299-42-3 9294
6
Pseudoephedrine Approved Phase 4 90-82-4 7028
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Desflurane Approved Phase 4 57041-67-5 42113
9
Budesonide Approved Phase 4 51333-22-3 63006 5281004
10
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
11
Morphine Approved, Investigational Phase 4 57-27-2 5288826
12
Sodium citrate Approved, Investigational Phase 4 68-04-2
13
Sodium oxybate Approved Phase 4 502-85-2 5360545
14
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
15
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
16
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
17
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
18
Losartan Approved Phase 4 114798-26-4 3961
19
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
20
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
21
Pantoprazole Approved Phase 4 102625-70-7 4679
22
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
23
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
24
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
25
Eplerenone Approved Phase 4 107724-20-9 150310 443872
26
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
27
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
28
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
31
Finasteride Approved Phase 4 98319-26-7 57363
32
Ethanol Approved Phase 4 64-17-5 702
33
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
34
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
35
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
36
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
37
Zolpidem Approved Phase 4 82626-48-0 5732
38
Promethazine Approved, Investigational Phase 4 60-87-7 4927
39
Liraglutide Approved Phase 4 204656-20-2 44147092
40
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
41
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
42
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
43
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
44
Metformin Approved Phase 4 657-24-9 14219 4091
45
Carbidopa Approved Phase 4 28860-95-9 34359
46
Levodopa Approved Phase 4 59-92-7 6047
47
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
48
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
49
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
50
Norepinephrine Approved Phase 4 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 2068)
# Name Status NCT ID Phase Drugs
1 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
2 Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study Unknown status NCT00912457 Phase 4 donepezil;placebo
3 Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability Unknown status NCT03890939 Phase 4
4 Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients Unknown status NCT01524510 Phase 4
5 Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients Unknown status NCT01590420 Phase 4
6 Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study Unknown status NCT01428570 Phase 4
7 Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo Unknown status NCT02820441 Phase 4 Zopiclone;Placebo
8 Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Trial. Unknown status NCT02630121 Phase 4 Oxymetazoline Hydrochloride;Placebo
9 Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption Unknown status NCT02371473 Phase 4 Acetazolamide-placebo;Placebo-acetazolamide
10 Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study Unknown status NCT02325089 Phase 4
11 Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients. Unknown status NCT01771406 Phase 4 Nebivolol
12 Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform Unknown status NCT01505959 Phase 4
13 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients Unknown status NCT01796769 Phase 4
14 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
15 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
16 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
17 Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing Unknown status NCT00299910 Phase 4 Montelukast
18 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
19 Randomised Monocentric -Controlled Study to Evaluate the Efficacy and Stability of Dexmedetomidine Sedation Compared to Propofol Sedation in the Routinely Diagnostic Examination: Drug Induced Sleep Endoscopy Unknown status NCT03892122 Phase 4 Propofol Fresenius;Dexmedetomidine
20 CPAP Effect on Nocturnal Evolution of Chemosensitivity Determinants in Sleep Apnea-hypopnea Patients With Isolated Nocturnal Hypertension or Day-nigh Sustained Hypertension Completed NCT02398032 Phase 4
21 The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients Completed NCT00480870 Phase 4 donepezil;Placebo
22 Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH Completed NCT00772044 Phase 4
23 Phase 4 Study of the Relationship Between the Oxidative Stress and the Development of Cardiovascular Complications in the Sleep Apnea-hypopnea Syndrome (SAHS). Effect of the Treatment With CPAP Completed NCT00487929 Phase 4
24 The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression Completed NCT04162743 Phase 4 Trazodone;Placebo oral tablet
25 Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome Completed NCT02717780 Phase 4 Fentanyl and sevoflurane;Remifentanil and desflurane
26 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
27 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
28 Does Nasal Decongestion Improve Obstructive Sleep Apnea ? Completed NCT00630474 Phase 4 xylometazoline
29 PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Completed NCT01532050 Phase 4
30 Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure Completed NCT00633711 Phase 4
31 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate
32 Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial Completed NCT02425202 Phase 4 Ketamine
33 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
34 Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
35 Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS). Completed NCT01508754 Phase 4
36 Nitrate and Oxidative Stress in Sleep Apnea Syndrome. Effect of Continuous Positive Airway Pressure Completed NCT00547937 Phase 4
37 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
38 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Completed NCT01699126 Phase 4 Statin
39 Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension. Completed NCT00409487 Phase 4 Valsartant treatment
40 The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea Completed NCT02714400 Phase 4 Venlafaxine;Placebo
41 Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment Completed NCT00765713 Phase 4
42 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome: Pulse Wave Velocity, Inflammatory and Oxidative Stress Markers Completed NCT01635010 Phase 4
43 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance Completed NCT00612157 Phase 4 Eszopiclone;Placebo control
44 Randomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea - RICCADSA Trial Completed NCT00519597 Phase 4
45 SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea. Completed NCT00811213 Phase 4
46 Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea Completed NCT00729963 Phase 4 Sibutramine
47 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
48 Prospective, Randomized, Placebo Controlled Trial Assessing the Effects of Ezopiclone on the Quality of Overnight Polysomnography and CPAP Titration Completed NCT00507117 Phase 4 Lunesta;Placebo control
49 Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea Completed NCT01344759 Phase 4 Dexmedetomidine;Propofol
50 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo

Search NIH Clinical Center for Sleep Apnea

Cochrane evidence based reviews: sleep apnea syndromes

Sources

Genetic Tests for Sleep Apnea

About this section

Genetic tests related to Sleep Apnea:

# Genetic test Affiliating Genes
1 Sleep Apnea 29
Sources

Anatomical Context for Sleep Apnea

About this section

MalaCards organs/tissues related to Sleep Apnea:

40
Heart, Endothelial, Tongue, Brain, Liver, Kidney, Eye
Sources

Publications for Sleep Apnea

About this section

Articles related to Sleep Apnea:

(show top 50) (show all 30021)
# Title Authors PMID Year
1
De novo truncating mutations in AHDC1 in individuals with syndromic expressive language delay, hypotonia, and sleep apnea. 6 61
24791903 2014
2
Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York. 61 42
33550849 2021
3
Adherence in children using positive airway pressure therapy: a big-data analysis. 42
33334566 2020
4
Sleep-disordered breathing: clinical features, pathophysiology and diagnosis. 42
33378547 2017
5
Post-operative outcomes and anesthesia type in total hip arthroplasty in patients with obstructive sleep apnea: A retrospective analysis of the State Inpatient Databases. 61
33348291 2021
6
A Quality Improvement Project for Monitoring Surgical Patients With Obstructive Sleep Apnea. 61
33793177 2021
7
A new approach to the clinical subclassification of heart failure with preserved ejection fraction. 61
33529665 2021
8
LncRNA XIST promotes inflammation by downregulating GRα expression in the adenoids of children with OSAHS. 61
33791009 2021
9
Analysis and visualization of sleep stages based on deep neural networks. 61
33763623 2021
10
Days Needed for the Disappearance of a Cough Due to the Use of an Angiotensin-Converting Enzyme Inhibitor and Identification of Predisposing Factors Associated With Its Appearance in a Clinical Cohort of Hypertensive Patients. 61
33188549 2021
11
Uvulopalatopharyngoplasty. 61
33581977 2021
12
The prevalence of sleep impairments and predictors of sleep quality among patients with asthma. 61
31903810 2021
13
Topical Triamcinolone on "Sweet Spots" to Block Dynamic Pain after Tonsillectomy and Uvulo-Palato-Pharyngo-Plasty. 61
32909450 2021
14
Perceptual snoring as a basis for a psychoacoustical modeling and clinical patient profiling. 61
33797031 2021
15
Use of mandibular advancement devices for the treatment of primary snoring with or without obstructive sleep apnea (OSA): A systematic review. 61
33326914 2021
16
[Obstructive sleep apnea syndrome in children]. 61
33730248 2021
17
Home respiratory polygraphy in obstructive sleep apnea syndrome in children: Comparison with a screening questionnaire. 61
33535090 2021
18
Impact of obstructive sleep apnea on cardiovascular risk in patients with acromegaly. 61
33601232 2021
19
Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. 61
33179591 2021
20
[Evaluation of clinical application of new remote radar monitoring equipment for obstructive sleep apnea]. 61
33794623 2021
21
Bariatric surgery may provide better protection than uvulopalatopharyngoplasty against major adverse cardiovascular events in obese patients with obstructive sleep apnea. 61
33423961 2021
22
Comparison of the effect of weight change, simulated computational continuous positive airway pressure treatment and positional therapy on severity of sleep apnea. 61
32557941 2021
23
Home Sleep Testing to Direct Upper Airway Stimulation Therapy Optimization for Sleep Apnea. 61
32865831 2021
24
Obstructive Sleep Apnea-Induced Neurogenic Nocturnal Hypertension: A Potential Role of Renal Denervation? 61
33641363 2021
25
The clinical impacts of sleep apnea on mortality and allograft function in kidney transplant patients: A meta-analysis. 61
33287952 2021
26
Treatment for patients with sleep apnea on opioids for chronic pain: results of the OpSafe trial. 61
33382032 2021
27
Portable pediatric sleep diagnostics: 2 measures closer to reliable home sleep apnea tests for all ages. 61
33551022 2021
28
Real-Time, Intraoperative, Ultrasound-Assisted Transoral Robotic Surgery for Obstructive Sleep Apnea. 61
33085091 2021
29
What Is Central Sleep Apnea in Adults? 61
33792532 2021
30
Maxillomandibular advancement for treatment of obstructive sleep apnea. 61
33795083 2021
31
A one-arm surgical trial of obstructive sleep apnea (OSA) patients before and 12 months after Bilateral Internal Ramus Distraction of the mandible (BIRD). 61
33567348 2021
32
A Novel Model to Estimate Key Obstructive Sleep Apnea Endotypes from Standard Polysomnography and Clinical Data and Their Contribution to Obstructive Sleep Apnea Severity. 61
33064953 2021
33
Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. 61
33226332 2021
34
Circulating levels of clusterin and complement factor H in patients with obstructive sleep apnea. 61
33666516 2021
35
A consideration of factors affecting palliative oral appliance effectiveness for obstructive sleep apnea: a scoping review. 61
33196434 2021
36
Adherence with positive airway pressure therapy for obstructive sleep apnea in developing vs. developed countries: a big data study. 61
33206044 2021
37
Obstructive Sleep Apnea and Chronic Insomnia Disorder: Updated Guidelines from the VA/DoD. 61
33788525 2021
38
Acetazolamide for central sleep apnea: teaching an old drug new tricks? 61
33792537 2021
39
Reduced Recovery Times with Total Intravenous Anesthesia in Patients with Obstructive Sleep Apnea. 61
33141982 2021
40
Interhemispheric sleep depth coherence predicts driving safety in sleep apnea. 61
32441843 2021
41
Obstructive Sleep Apnea, Glucose Tolerance, and β-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. 61
33547205 2021
42
One-month of a low-energy diet, with no additional effect of high-protein, reduces Obstructive Sleep Apnea severity and improve metabolic parameters in obese males. 61
33745625 2021
43
An algorithm for the sedation of patients with obstructive sleep apnea by non-anesthesiologists. 61
33565898 2021
44
Molecular determinants of obstructive sleep apnea. 61
33592435 2021
45
Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. 61
33135629 2021
46
Diagnosis of Sleep Apnea Syndrome in the Intensive Care Unit: A Case Series of Survivors of Hypercapnic Respiratory Failure. 61
33171053 2021
47
Self-reported view on work capacity predicts abnormal Oxford Sleep Resistance Test results in patients with obstructive sleep apnea. 61
33196435 2021
48
Drug-induced sleep endoscopy directed surgery improves polysomnography measures in overweight and obese children with obstructive sleep apnea. 61
33372808 2021
49
Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. 61
33567870 2021
50
Long-term stability of results following surgery for obstructive sleep apnea (OSA). 61
33797601 2021
Sources

Variations for Sleep Apnea

About this section

ClinVar genetic disease variations for Sleep Apnea:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 AHDC1 NM_001029882.3(AHDC1):c.2371_2372TG[1] (p.Cys791fs) Microsatellite Pathogenic 133326 rs587779766 GRCh37: 1:27876253-27876254
GRCh38: 1:27549742-27549743
2 AHDC1 NM_001029882.3(AHDC1):c.2898del (p.Tyr967fs) Deletion Pathogenic 133327 rs587779767 GRCh37: 1:27875729-27875729
GRCh38: 1:27549218-27549218
3 AHDC1 NM_001029882.3(AHDC1):c.2547del (p.Ser850fs) Deletion Pathogenic 133328 rs587779768 GRCh37: 1:27876080-27876080
GRCh38: 1:27549569-27549569
4 AHDC1 NM_001029882.3(AHDC1):c.2371_2372TG[1] (p.Cys791fs) Microsatellite Pathogenic 133326 rs587779766 GRCh37: 1:27876253-27876254
GRCh38: 1:27549742-27549743
5 AHDC1 NM_001029882.3(AHDC1):c.2898del (p.Tyr967fs) Deletion Pathogenic 133327 rs587779767 GRCh37: 1:27875729-27875729
GRCh38: 1:27549218-27549218
6 AHDC1 NM_001029882.3(AHDC1):c.2547del (p.Ser850fs) Deletion Pathogenic 133328 rs587779768 GRCh37: 1:27876080-27876080
GRCh38: 1:27549569-27549569
7 MT-CO3 NC_012920.1:m.9355A>T SNV Uncertain significance 523307 rs1556423663 GRCh37: MT:9355-9355
GRCh38: MT:9355-9355
Sources

Expression for Sleep Apnea

About this section
Search GEO for disease gene expression data for Sleep Apnea.
Sources

Pathways for Sleep Apnea

About this section

Pathways related to Sleep Apnea according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.13 TNF LEPR LEP INS IL6 IGF1
2
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 13.31 TNF REN NPPB LEPR LEP INS
3
p70S6K Signaling 63
Show member pathways
 13.01 REN INS IL6 IGF1 HIF1A ACE
4
IL-9 Signaling Pathways 64
Show member pathways
 12.74 TNF LEP INS IL6 ADIPOQ
5
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.45 LEPR LEP INS IGF1 ADIPOQ
7
Selenium Micronutrient Network 1
Show member pathways
 12.28 TNF INS IL6 CRP APOE
8
Dilated cardiomyopathy 36
Show member pathways
 12.2 TNF IL6 IGF1 EDN1 ACE
9
IL-1 Family Signaling Pathways 64
Show member pathways
 12.18 TNF IL6 EDN1 CXCL8
10
Peptide hormone metabolism 65
Show member pathways
 12.17 REN LEP INS IGF1 GHRL ACE
11
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.1 TNF NPPB IGF1 EDN1
12
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.05 TNF PHOX2B IL6 HTR2A HIF1A CXCL8
13
Spinal Cord Injury 1
11.96 TNF LEP IL6 CXCL8
14
Interleukin-4 and 13 signaling 65
11.93 TNF IL6 HIF1A CXCL8
15
HIF-1 signaling pathway 36
11.93 INS IL6 IGF1 HIF1A EDN1
16
Senescence and Autophagy in Cancer 1
11.89 INS IL6 IGF1 CXCL8
17
AGE-RAGE signaling pathway in diabetic complications 36
11.86 TNF IL6 EDN1 CXCL8
18
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.83 LEP INS IL6 IGF1 ADIPOQ
19
Pertussis 36
11.73 TNF IL6 CXCL8
20
Renin secretion 36
11.68 REN EDN1 ACE
21
Adipocytokine signaling pathway 36
11.66 TNF LEPR LEP ADIPOQ
22
HIF-1-alpha transcription factor network 1
11.65 LEP HIF1A EDN1
23
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.63 TNF IL6 CXCL8
24
Legionellosis 36
11.58 TNF IL6 CXCL8
25
ATF-2 transcription factor network 1
11.56 INS IL6 CXCL8
26
Hepatitis C and Hepatocellular Carcinoma 1
11.52 IL6 HIF1A CXCL8
27
Signaling events mediated by PTP1B 1
11.5 LEPR LEP INS
28
Malaria 36
11.5 TNF IL6 CXCL8